RT Journal Article
T1 Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes.
A1 Vrancken, Bram
A1 Cuypers, Lize
A1 Pérez, Ana Belen
A1 Chueca, Natalia
A1 Anton-Basantas, Joaquin
A1 de la Iglesia, Alberto
A1 Fuentes, Javier
A1 Pineda, Juan Antonio
A1 Téllez, Francisco
A1 Bernal, Enrique
A1 Rincón, Pilar
A1 Von Wichman, Miguel Angel
A1 Fuentes, Ana
A1 Vera, Francisco
A1 Rivero-Juárez, Antonio
A1 Jiménez, Miguel
A1 Vandamme, Anne-Mieke
A1 García, Federico
K1 Elimination
K1 European Union
K1 HCV
K1 National strategy
K1 PWID
K1 Spain
AB As of 2018, the majority of Western European countries – including Spain – have lifted restrictions to therapy based on disease severity in the context of HCV infections.1 Long overdue, most national elimination programmes now also include access to care for people who inject drugs (PWID),2 who are at the core of ongoing HCV transmission.3 Macías et al.4 have recently shown in this Journal that high viral cure rates can be achieved in this group, hereby providing evidence that targeting PWID in treatment programmes is worthwhile. However, the extent to which such national efforts can reduce the HCV burden not only depends on the uptake into care and treatment success rates, it is also determined by the relative importance of within-country transmission and virus importation from elsewhere.
PB Elsevier
SN 0168-8278
YR 2019
FD 2019-10-01
LK http://hdl.handle.net/10668/14584
UL http://hdl.handle.net/10668/14584
LA en
NO Vrancken B, Cuypers L, Pérez AB, Chueca N, Anton-Basantas J, de la Iglesia A, et al. Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes. J Hepatol. 2019 Dec;71(6):1270-1272.
DS RISalud
RD Apr 10, 2025